Identification of potent biodegradable adjuvants that efficiently break self-tolerance--a key issue in the development of therapeutic vaccines

Maria Ringvall, Elisabeth J M Huijbers, Parvin Ahooghalandari, Ludmila Alekseeva, Tatyana Andronova, Anna-Karin Olsson, Lars Hellman

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Monoclonal antibodies are used successfully in the treatment of many human disorders. However, these antibodies are expensive and have in many countries put a major strain on the health care economy. Therapeutic vaccines, directed against the same target molecules, may offer a solution to this problem. Vaccines usually involve lower amount of recombinant protein, approximately 10,000-20,000 times less, which is significantly more cost effective. Attempts to develop such therapeutic vaccines have also been made. However, their efficacy has been limited by the lack of potent immunostimulatory compounds, adjuvants, for human use. To address this problem we have conducted a broad screening for adjuvants that can enhance the efficacy of therapeutic vaccines, whilst at the same time being non-toxic and biodegradable. We have now identified adjuvants that show these desired characteristics. A combination of Montanide ISA720 and phosphorothioate stabilized CpG stimulatory DNA, induced similar or even higher anti-self-antibody titers compared to Freund's adjuvant, currently the most potent, but also toxic, adjuvant available. This finding removes one of the major limiting factors in the field and facilitates the development of a broad range of novel therapeutic vaccines.

Original languageEnglish
Pages (from-to)48-52
Number of pages5
JournalVaccine
Volume28
Issue number1
DOIs
Publication statusPublished - 10 Dec 2009

Cite this

Ringvall, Maria ; Huijbers, Elisabeth J M ; Ahooghalandari, Parvin ; Alekseeva, Ludmila ; Andronova, Tatyana ; Olsson, Anna-Karin ; Hellman, Lars. / Identification of potent biodegradable adjuvants that efficiently break self-tolerance--a key issue in the development of therapeutic vaccines. In: Vaccine. 2009 ; Vol. 28, No. 1. pp. 48-52.
@article{6ef5883ae0724ac9bccacc2d1d5ea658,
title = "Identification of potent biodegradable adjuvants that efficiently break self-tolerance--a key issue in the development of therapeutic vaccines",
abstract = "Monoclonal antibodies are used successfully in the treatment of many human disorders. However, these antibodies are expensive and have in many countries put a major strain on the health care economy. Therapeutic vaccines, directed against the same target molecules, may offer a solution to this problem. Vaccines usually involve lower amount of recombinant protein, approximately 10,000-20,000 times less, which is significantly more cost effective. Attempts to develop such therapeutic vaccines have also been made. However, their efficacy has been limited by the lack of potent immunostimulatory compounds, adjuvants, for human use. To address this problem we have conducted a broad screening for adjuvants that can enhance the efficacy of therapeutic vaccines, whilst at the same time being non-toxic and biodegradable. We have now identified adjuvants that show these desired characteristics. A combination of Montanide ISA720 and phosphorothioate stabilized CpG stimulatory DNA, induced similar or even higher anti-self-antibody titers compared to Freund's adjuvant, currently the most potent, but also toxic, adjuvant available. This finding removes one of the major limiting factors in the field and facilitates the development of a broad range of novel therapeutic vaccines.",
keywords = "Adjuvants, Immunologic/pharmacology, Animals, Antibody Formation, Autoantibodies/blood, DNA/immunology, Enzyme-Linked Immunosorbent Assay, Female, Freund's Adjuvant/immunology, Immunoglobulin E/immunology, Immunoglobulin Heavy Chains/immunology, Mannitol/analogs & derivatives, Oleic Acids/immunology, Oligodeoxyribonucleotides, RNA, Double-Stranded/immunology, Rats, Rats, Wistar, Self Tolerance/immunology, Vaccines/immunology",
author = "Maria Ringvall and Huijbers, {Elisabeth J M} and Parvin Ahooghalandari and Ludmila Alekseeva and Tatyana Andronova and Anna-Karin Olsson and Lars Hellman",
year = "2009",
month = "12",
day = "10",
doi = "10.1016/j.vaccine.2009.09.122",
language = "English",
volume = "28",
pages = "48--52",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "1",

}

Identification of potent biodegradable adjuvants that efficiently break self-tolerance--a key issue in the development of therapeutic vaccines. / Ringvall, Maria; Huijbers, Elisabeth J M; Ahooghalandari, Parvin; Alekseeva, Ludmila; Andronova, Tatyana; Olsson, Anna-Karin; Hellman, Lars.

In: Vaccine, Vol. 28, No. 1, 10.12.2009, p. 48-52.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Identification of potent biodegradable adjuvants that efficiently break self-tolerance--a key issue in the development of therapeutic vaccines

AU - Ringvall, Maria

AU - Huijbers, Elisabeth J M

AU - Ahooghalandari, Parvin

AU - Alekseeva, Ludmila

AU - Andronova, Tatyana

AU - Olsson, Anna-Karin

AU - Hellman, Lars

PY - 2009/12/10

Y1 - 2009/12/10

N2 - Monoclonal antibodies are used successfully in the treatment of many human disorders. However, these antibodies are expensive and have in many countries put a major strain on the health care economy. Therapeutic vaccines, directed against the same target molecules, may offer a solution to this problem. Vaccines usually involve lower amount of recombinant protein, approximately 10,000-20,000 times less, which is significantly more cost effective. Attempts to develop such therapeutic vaccines have also been made. However, their efficacy has been limited by the lack of potent immunostimulatory compounds, adjuvants, for human use. To address this problem we have conducted a broad screening for adjuvants that can enhance the efficacy of therapeutic vaccines, whilst at the same time being non-toxic and biodegradable. We have now identified adjuvants that show these desired characteristics. A combination of Montanide ISA720 and phosphorothioate stabilized CpG stimulatory DNA, induced similar or even higher anti-self-antibody titers compared to Freund's adjuvant, currently the most potent, but also toxic, adjuvant available. This finding removes one of the major limiting factors in the field and facilitates the development of a broad range of novel therapeutic vaccines.

AB - Monoclonal antibodies are used successfully in the treatment of many human disorders. However, these antibodies are expensive and have in many countries put a major strain on the health care economy. Therapeutic vaccines, directed against the same target molecules, may offer a solution to this problem. Vaccines usually involve lower amount of recombinant protein, approximately 10,000-20,000 times less, which is significantly more cost effective. Attempts to develop such therapeutic vaccines have also been made. However, their efficacy has been limited by the lack of potent immunostimulatory compounds, adjuvants, for human use. To address this problem we have conducted a broad screening for adjuvants that can enhance the efficacy of therapeutic vaccines, whilst at the same time being non-toxic and biodegradable. We have now identified adjuvants that show these desired characteristics. A combination of Montanide ISA720 and phosphorothioate stabilized CpG stimulatory DNA, induced similar or even higher anti-self-antibody titers compared to Freund's adjuvant, currently the most potent, but also toxic, adjuvant available. This finding removes one of the major limiting factors in the field and facilitates the development of a broad range of novel therapeutic vaccines.

KW - Adjuvants, Immunologic/pharmacology

KW - Animals

KW - Antibody Formation

KW - Autoantibodies/blood

KW - DNA/immunology

KW - Enzyme-Linked Immunosorbent Assay

KW - Female

KW - Freund's Adjuvant/immunology

KW - Immunoglobulin E/immunology

KW - Immunoglobulin Heavy Chains/immunology

KW - Mannitol/analogs & derivatives

KW - Oleic Acids/immunology

KW - Oligodeoxyribonucleotides

KW - RNA, Double-Stranded/immunology

KW - Rats

KW - Rats, Wistar

KW - Self Tolerance/immunology

KW - Vaccines/immunology

U2 - 10.1016/j.vaccine.2009.09.122

DO - 10.1016/j.vaccine.2009.09.122

M3 - Article

VL - 28

SP - 48

EP - 52

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 1

ER -